BRPI1015940A2 - métodos e composições de inibidores de pi-3 quinase para tratar fibrose - Google Patents
métodos e composições de inibidores de pi-3 quinase para tratar fibroseInfo
- Publication number
- BRPI1015940A2 BRPI1015940A2 BRPI1015940A BRPI1015940A BRPI1015940A2 BR PI1015940 A2 BRPI1015940 A2 BR PI1015940A2 BR PI1015940 A BRPI1015940 A BR PI1015940A BR PI1015940 A BRPI1015940 A BR PI1015940A BR PI1015940 A2 BRPI1015940 A2 BR PI1015940A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- kinase inhibitor
- treating fibrosis
- inhibitor methods
- methods
- Prior art date
Links
- 206010016654 Fibrosis Diseases 0.000 title 1
- 229940116355 PI3 kinase inhibitor Drugs 0.000 title 1
- 230000004761 fibrosis Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16790509P | 2009-04-09 | 2009-04-09 | |
| US23574009P | 2009-08-21 | 2009-08-21 | |
| PCT/US2010/030420 WO2010118250A2 (en) | 2009-04-09 | 2010-04-08 | Methods and compositions of pi-3 kinase inhibitors for treating fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1015940A2 true BRPI1015940A2 (pt) | 2016-04-19 |
Family
ID=42936877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1015940A BRPI1015940A2 (pt) | 2009-04-09 | 2010-04-08 | métodos e composições de inibidores de pi-3 quinase para tratar fibrose |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20120046333A1 (OSRAM) |
| EP (1) | EP2416771A4 (OSRAM) |
| JP (1) | JP2012523429A (OSRAM) |
| KR (1) | KR20120018761A (OSRAM) |
| CN (1) | CN102395363A (OSRAM) |
| AU (1) | AU2010234360A1 (OSRAM) |
| BR (1) | BRPI1015940A2 (OSRAM) |
| CA (1) | CA2754343A1 (OSRAM) |
| MX (1) | MX2011010631A (OSRAM) |
| WO (1) | WO2010118250A2 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102727478A (zh) * | 2012-06-14 | 2012-10-17 | 合肥博太医药生物技术发展有限公司 | 视黄酸及其衍生物在制备防治肾纤维化药物中的应用 |
| TW202214254A (zh) | 2013-03-01 | 2022-04-16 | 美商英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途 |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| CA2939121C (en) | 2014-01-28 | 2020-11-24 | Mayo Foundation For Medical Education And Research | Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease |
| CN110917351A (zh) * | 2018-09-20 | 2020-03-27 | 华中科技大学同济医学院附属同济医院 | Mbd2抑制剂在预防和治疗纤维化疾病中的用途 |
| JP2022065212A (ja) * | 2019-02-28 | 2022-04-27 | 国立大学法人京都大学 | 組織線維化による疾患の予防又は治療のための医薬 |
| EP3946330A1 (en) * | 2019-03-29 | 2022-02-09 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders |
| EP4259207A4 (en) * | 2020-12-10 | 2025-02-26 | Children's Hospital Medical Center | IMPROVED NANOPARTICLE RELEASE SYSTEMS |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004075917A1 (ja) * | 2003-02-28 | 2004-09-10 | Toudai Tlo, Ltd. | 器官または組織の線維化抑制剤 |
| EP2301533A1 (en) * | 2004-07-09 | 2011-03-30 | University of Pittsburgh | Wortmannin Analogs and Method of Using Same |
| CN101180055A (zh) * | 2005-05-27 | 2008-05-14 | 拜耳医药保健股份公司 | 用于治疗疾病的包含二芳基脲的组合治疗 |
| CA2609387A1 (en) * | 2005-05-27 | 2006-11-30 | Bayer Healthcare Ag | Combination therapy comprising diaryl ureas for treating diseases |
| PL1965790T3 (pl) * | 2005-12-30 | 2012-05-31 | Arizona Board Of Regents Acting On Behalf Of The Univ Of Arizona | Metabolity analogów wortmaniny i sposoby ich stosowania |
| JO2660B1 (en) * | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
-
2010
- 2010-04-08 EP EP10762450A patent/EP2416771A4/en not_active Withdrawn
- 2010-04-08 BR BRPI1015940A patent/BRPI1015940A2/pt not_active IP Right Cessation
- 2010-04-08 WO PCT/US2010/030420 patent/WO2010118250A2/en not_active Ceased
- 2010-04-08 JP JP2012504871A patent/JP2012523429A/ja active Pending
- 2010-04-08 KR KR1020117026616A patent/KR20120018761A/ko not_active Ceased
- 2010-04-08 CN CN2010800151213A patent/CN102395363A/zh active Pending
- 2010-04-08 AU AU2010234360A patent/AU2010234360A1/en not_active Abandoned
- 2010-04-08 CA CA2754343A patent/CA2754343A1/en not_active Abandoned
- 2010-04-08 MX MX2011010631A patent/MX2011010631A/es not_active Application Discontinuation
- 2010-04-08 US US13/262,906 patent/US20120046333A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2416771A2 (en) | 2012-02-15 |
| CN102395363A (zh) | 2012-03-28 |
| US20120046333A1 (en) | 2012-02-23 |
| EP2416771A4 (en) | 2012-10-31 |
| CA2754343A1 (en) | 2010-10-14 |
| WO2010118250A3 (en) | 2011-03-31 |
| JP2012523429A (ja) | 2012-10-04 |
| WO2010118250A2 (en) | 2010-10-14 |
| AU2010234360A1 (en) | 2011-09-29 |
| MX2011010631A (es) | 2012-01-20 |
| KR20120018761A (ko) | 2012-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR25C1006I1 (fr) | Inhibiteurs de pyrazolyl-quinoxaline kinase | |
| CY2020024I2 (el) | Αναστολεiς βητα-λακταμασων | |
| BRPI1011129A2 (pt) | métodos e compostos inibidores de janus cinase | |
| BRPI0918970A2 (pt) | algoritmo para projeto de inibidores irreversíveis | |
| BRPI0914652A2 (pt) | compostos e composições como inibidores de quinase | |
| SMT201600104B (it) | Inibitore di bromodominio benzodiazepinico | |
| ATE522535T1 (de) | Pyrrolotriazin-kinasehemmer | |
| BRPI0915205A2 (pt) | compostos e composições úteis para o tratamento de malária | |
| BRPI1015940A2 (pt) | métodos e composições de inibidores de pi-3 quinase para tratar fibrose | |
| BRPI0912668A2 (pt) | composto e composições como inibidores de quinase | |
| BRPI0920135A2 (pt) | imidazopiridazinacarbonitrilos úteis como inibidores de quinase | |
| BRPI1014572A2 (pt) | imidazoprazinas para uso como inibidores de cinase | |
| ATE519763T1 (de) | Pyrrolopyrazin-kinasehemmer | |
| SMT201400133B (it) | Composti e composizioni come inibitori di protein chinasi | |
| BRPI0913879A2 (pt) | fenilpirazinonas como inibidores de quinase | |
| EP2498607A4 (en) | Kinase Inhibitors | |
| EP2493313A4 (en) | Kinase Inhibitors | |
| BRPI1009112A2 (pt) | inibidores de tirosina quinase de bruton | |
| BRPI0918846A2 (pt) | inibidores de cinase heterocíclica | |
| EP2246336A4 (en) | FIBROSIS INHIBITORS | |
| EP2558099A4 (en) | Kinase inhibitors | |
| BRPI1011325A2 (pt) | composições e métodos para o tratamento de inflamação | |
| BRPI1008326A2 (pt) | Composições e métodos para controlar nanatódeos | |
| BRPI0915984A2 (pt) | método para inibição da corrosão | |
| BRPI0910979A2 (pt) | compostos e composições como inibidores de quinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |